Hideaki Isago

Hideaki Isago

Auto-generated profile, based on publicly available information

Hideaki Isago

The University of Tokyo

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
BUBaasanjav Uranbileg
Baasanjav Uranbileg
HIHideaki Isago
Hideaki Isago
ESEri Sakai
Eri Sakai
MKMasayuki Kubota
Masayuki Kubota
YSYuko Saito
Yuko Saito
MKMakoto Kurano
Makoto Kurano
Introduction: Alzheimer’s disease (AD) is associated with disturbed metabolism, prompting investigations into specific metabolic pathways that may contribute to its pathogenesis and pathology. Sphingolipids have garnered attention due to their known physiological impact on various diseases.Methods: We conducted comprehensive profiling of sphingolipids to understand their possible role in AD. Sphingolipid levels were measured in AD brains, Cerad score B brains, and controls, as well as in induced pluripotent stem (iPS) cells (AD, PS, and control), using liquid chromatography mass spectrometry.Results: AD brains exhibited higher levels of sphingosine (Sph), total ceramide 1-phosphate (Cer1P), and total ceramide (Cer) compared to control and Cerad-B brains. Deoxy-ceramide (Deoxy-Cer) was elevated in Cerad-B and AD brains compared to controls, with increased sphingomyelin (SM) levels exclusively in Cerad-B brains. Analysis of cell lysates revealed elevated dihydroceramide (dhSph), total Cer1P, and total SM in AD and PS cells versus controls. Multivariate analysis highlighted the relevance of Sph, Cer, Cer1P, and SM in AD pathology. Machine learning identified Sph, Cer, and Cer1P as key contributors to AD.Discussion: Our findings suggest the potential importance of Sph, Cer1P, Cer, and SM in the context of AD pathology. This underscores the significance of sphingolipid metabolism in understanding and potentially targeting mechanisms underlying AD.

16 July 2024 in The FASEB Journal
Verified
Journal Article
Open access
BUBaasanjav Uranbileg
Baasanjav Uranbileg
HIHideaki Isago
Hideaki Isago
HNHitoshi Nakayama
Hitoshi Nakayama
DJDaisuke Jubishi
Daisuke Jubishi
KOKoh Okamoto
Koh Okamoto
MKMakoto Kurano
Makoto Kurano
The COVID‐19 pandemic, caused by SARS‐CoV‐2, has had a significant worldwide impact, affecting millions of people. COVID‐19 is characterized by a heterogenous clinical phenotype, potentially involving hyperinflammation and prolonged tissue damage, although the exact underlying mechanisms are yet to be fully understood. Sphingolipid metabolites, which govern cell survival and proliferation, have emerged as key players in inflammatory signaling and cytokine responses. Given the complex metabolic pathway of sphingolipids, this study aimed to understand their potential role in the pathogenesis of COVID‐19. We conducted a comprehensive examination of sphingolipid modulations across groups classified based on disease severity, incorporating a time‐course in serum and urine samples. Several sphingolipids, including sphingosine, lactosylceramide, and hexosylceramide, emerged as promising indicators of COVID‐19 severity, as validated by correlation analyses conducted on both serum and urine samples. Other sphingolipids, such as sphingosine 1‐phosphate, ceramides, and deoxy‐dihydroceramides, decreased in both COVID‐19 patients and individuals with non‐COVID infectious diseases. This suggests that these sphingolipids are not specifically associated with COVID‐19 but rather with pathological conditions caused by infectious diseases. Our analysis of urine samples revealed elevated levels of various sphingolipids, with changes dependent on disease severity, potentially highlighting the acute kidney injury associated with COVID‐19. This study illuminates the intricate relationship between disturbed sphingolipid metabolism, COVID‐19 severity, and clinical factors. These findings provide valuable insights into the broader landscape of inflammatory diseases.

18 January 2025 in Lung Cancer
Verified
Journal Article
Open access
KFKoki Fujii
Koki Fujii
MUMichiko Ueki
Michiko Ueki
MMMomoko Morishita
Momoko Morishita
HIHiroaki Ikushima
Hiroaki Ikushima
HIHideaki Isago
Hideaki Isago
HKHidenori Kage
Hidenori Kage
Molecular testing is recommended to patients with advanced non-small cell lung cancer (NSCLC) because those who receive targeted therapy have better prognosis than patients who don't. However, recent studies have raised concerns that first-line companion diagnostic testing at diagnosis may have lower detection rates than previously reported. Therefore, we sought to determine the utility of comprehensive genomic profiling (CGP) tests in NSCLC by analyzing a nation-wide database. We searched the Center for Cancer Genomics and Advanced Therapeutics database and downloaded clinical and genomic data from 3,240 lung cancer cases registered from June 2019 to August 2023. Patients undergoing tissue tests and plasma tests were analyzed separately. NSCLC with previously known driver mutations and those without were further analyzed separately. All 3,240 lung cancer patients were analyzed for the presence of germline findings. We found that 25 % of patients who had negative companion diagnostic results tested positive for driver oncogene mutations with indications for approved inhibitors when they underwent tissue CGP tests. Tissue CGP tests had lower detection rates for gene fusions compared with gene mutations (93 % for mutations and 73 % for fusions, p < 0.001), and plasma CGP tests had lower detection rates for both mutations and fusions compared with tissue testing (69 % for mutations and 37 % for fusions, p < 0.001). Finally, presumed germline pathogenic variants were detected in 3.9-5.3 % of NSCLC patients. NSCLC patients who tested negative for companion diagnostic tests benefited from CGP tests, especially with tissue-based panels. CGP tests detect germline findings in NSCLC patients at rates similar to previous reports.

1 September 2024 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
HIHideaki Isago
Hideaki Isago
Dyslipidemia is one of the most common diseases worldwide. As a component of metabolic syndrome, the prevalence and mechanism by which dyslipidemia promotes cardiovascular diseases has been well studied, although the relationship between pulmonary diseases is not well understood. Because the lung is a respiratory organ with a large surface area and is exposed to the environment outside the body, it continuously inhales various substances. As a result, pulmonary diseases have a vast diversity, including chronic inflammatory diseases, allergic diseases, cancers, and infectious diseases. Recently, growing evidence has suggested that dyslipidemia plays a role in the pathogenesis and prognosis of various pulmonary diseases. We herein review the current understanding of the relationship between dyslipidemia and pulmonary diseases, including chronic obstructive pulmonary diseases, asthma, and lung cancer, and infectious pulmonary diseases, including community-acquired pneumonia, tuberculosis, nontuberculous mycobacterial pulmonary disease, and COVID-19. In addition, we focus on recent evidence of the utility of statins, specifically 3-hydroxy-3-methylglutaryl-coA reductase inhibitors, in the prevention and treatment of the various pulmonary diseases described above.

25 December 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
TSTakuya Shimura
Takuya Shimura
HIHideaki Isago
Hideaki Isago
YMYoshifumi Morita
Yoshifumi Morita
RORyunosuke Ohkawa
Ryunosuke Ohkawa
NYNaoyuki Yoshikawa
Naoyuki Yoshikawa
MKMakoto Kurano
Makoto Kurano
Paraoxonase-1 (PON1) is a crucial esterase in cardiovascular health, closely associated with HDL and known for its antioxidant and anti-inflammatory properties. Reduced PON1 activity has been linked to cardiovascular diseases. Lysophospholipids (LysoPLs), essential for cellular processes and immune responses, are implicated in the pathogenesis of cardiovascular diseases and are bound to lipoproteins, contributing to their diverse effects. Thus, we hypothesize that the relationship between PON1 and cardiovascular diseases may involve the modulation of LysoPLs by PON1. This study aims to investigate how PON1 potentially influences LysoPLs. We quantified the levels of LysoPLs in HepG2 cells by using liquid chromatography-mass spectrometry, manipulating PON1 expression or knockdown. In cells overexpressing PON1, there was a significant increase in cellular levels of lysophosphatidylserine (LysoPS) and medium levels of LysoPS. Conversely, in cells with PON-1 knockdown, cellular levels of lysophosphatidylcholine (LysoPC) and medium levels of LysoPC showed a significant decrease. PON1 is involved in modulating LysoPLs, which contribute to the antioxidant and anti-inflammatory properties of HDL, often attributed to PON1.

9 August 2024 in Respiratory Investigation
Verified
Journal Article
Open access
HKHidenori Kage
Hidenori Kage
SKShinji Kohsaka
Shinji Kohsaka
KTKenji Tatsuno
Kenji Tatsuno
KWKousuke Watanabe
Kousuke Watanabe
ASAya Shinozaki-Ushiku
Aya Shinozaki-Ushiku
Katsutoshi OdaKatsutoshi Oda
Katsutoshi Oda
Background: Comprehensive cancer genomic profiling tests have recently been used clinically to guide optimal treatment. Currently approved tests use DNA from tissue or plasma samples to analyze a few hundred genes. RNA panels complement DNA panels to detect fusion and exon skipping. Methods: Between April 2017 and March 2022, we analyzed non-small cell lung cancer samples using Todai OncoPanel, a matched tumor/normal pair panel targeting both DNA and RNA. Publicly available genomic data was downloaded from the Center for Cancer Genomics and Advanced Therapeutics database on 2022/11/3. Results: Sixty non-small cell lung cancer (NSCLC) samples were analyzed. With the DNA panel, 32 samples (53%) had TP53 loss-of-function mutations. Among adenocarcinoma, 17 (33%) had EGFR activating mutations, and 6 (12%) had ERBB2 activating mutations. One BRCA1 and one BRCA2 pathogenic germline variant were also detected. With the RNA panel, 11 fusion genes were detected, all in adenocarcinoma. Specifically, EML4-ALK and KIF5B-RET were detected from one sample each, and 9 others were all novel fusions with unknown pathogenicity. In addition, 4 of 60 (7%) NSCLC samples harbored MET exon 14 skipping. Analysis of the Center for Cancer Genomics and Advanced Therapeutics database found 37 MET exon 14 splice site mutations in 1514 NSCLC samples (2%, p = 0.039). Conclusions: Analysis of NSCLC with Todai OncoPanel detected many druggable targets. Its RNA panel may detect MET exon 14 skipping with high sensitivity.